A new trading day began on Monday, with ProQR Therapeutics N.V (NASDAQ: PRQR) stock price down -6.47% from the previous day of trading, before settling in for the closing price of $4.33. PRQR’s price has ranged from $1.11 to $4.62 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 44.49% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 3.13%. With a float of $52.75 million, this company’s outstanding shares have now reached $78.46 million.
In terms of profitability, gross margin is 90.84%, operating margin of -185.03%, and the pretax margin is -139.15%.
ProQR Therapeutics N.V (PRQR) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of ProQR Therapeutics N.V is 35.41%, while institutional ownership is 22.17%.
ProQR Therapeutics N.V (PRQR) Performance Highlights and Predictions
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -0.08 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 3.13% per share during the next fiscal year.
ProQR Therapeutics N.V (NASDAQ: PRQR) Trading Performance Indicators
Here are ProQR Therapeutics N.V’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.29, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.50 in one year’s time.
Technical Analysis of ProQR Therapeutics N.V (PRQR)
Let’s dig in a bit further. During the last 5-days, its volume was 12.63 million. That was better than the volume of 0.49 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 88.42%. Additionally, its Average True Range was 0.37.
During the past 100 days, ProQR Therapeutics N.V’s (PRQR) raw stochastic average was set at 81.06%, which indicates a significant increase from 80.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 331.33% in the past 14 days, which was higher than the 137.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.10, while its 200-day Moving Average is $2.02. However, in the short run, ProQR Therapeutics N.V’s stock first resistance to watch stands at $4.30. Second resistance stands at $4.56. The third major resistance level sits at $4.74. If the price goes on to break the first support level at $3.87, it is likely to go to the next support level at $3.70. Assuming the price breaks the second support level, the third support level stands at $3.44.
ProQR Therapeutics N.V (NASDAQ: PRQR) Key Stats
With a market capitalization of 330.80 million, the company has a total of 81,355K Shares Outstanding. Currently, annual sales are 7,050 K while annual income is -30,430 K. The company’s previous quarter sales were 6,790 K while its latest quarter income was -2,900 K.
